iCAD Reports First Quarter 2018 Financial Results
Company Expects to Submit PowerLook Tomo Detection Version 2.0 for FDA Approval Shortly
Submission to be Based on Promising Results from Pivotal Clinical Reader Study
Conference call today at 4:30 p.m. ET
NASHUA, N.H. (May 14, 2018) – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader
providing innovative cancer detection and therapy solutions, today reported
financial results for the first quarter ended March 31, 2018.
First Quarter 2018 Financial Highlights:
• Total revenue of $6.3 million, down 7% year-over-year
• Gross profit of $4.5 million, or 71%
•GAAP Net Loss of $(3.3) million, or $(0.20) per
share
•Non-GAAP Adjusted EBITDA loss of $(2.4) million